Ifosfamide and Etoposide in Relapsed Refractory Childhood Acute Lymphoblastic Leukemia.
- Author:
Shung Shin KIM
;
Bin CHO
;
Dae Chul JEONG
;
Hack Ki KIM
- Publication Type:Original Article
- Keywords:
Ifosfamide;
Etoposide;
Relapsed childhood acute lymphoblastic leukemia
- MeSH:
Adult;
Bone Marrow;
Bone Marrow Transplantation;
Child;
Cystitis;
Doxorubicin;
Etoposide*;
Histocompatibility;
Humans;
Ifosfamide*;
Leukemia;
Mesna;
Mucositis;
Neutropenia;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*;
Prognosis;
Recurrence;
Siblings;
Teniposide;
Thrombocytopenia;
Tissue Donors
- From:Korean Journal of Pediatric Hematology-Oncology
1997;4(1):90-97
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The prognosis for children with relapsed acute lymphoblastic leukemia remains dismal. Ifosfamide has previously been shown to be active as a single agent and in combination with doxorubicin, etoposide, and teniposide in pediatric solid tumors, recurrent acute lymphoblastic leukemia and adult acute leukemia. We assessed the efficacy and the toxicity of the drug combination with ifosfamide and etoposide in patients with relapsed refractory acute lymphoblastic leukemia. METHODS: Between April 1995 and May 1996, twenty children aged 1 to 14 years with ALL in Catholic Medical Center, all heavily pretreated and in bone marrow relapse, were enrolled in this study. Drugs were given intravenously each day for 5 days at the following doses ; ifosfamide 1.8 g/m2/day, etoposide 100 mg/m2/day and mesna 1440 mg/ m2/day(as a uroprotectant) ; Cycles were repeated every 28 days for two cycles. RESULTS: 1) Twenty heavily pretreated patients were entered on study. At study entry, seventeen patients were in first relapse, two were in second relapse and one was in third relapse. 2) Six patients(30%) achieved complete remission, and eight patients(40%) achieved partial remission. Overall response rate was 70%. 3) Duration of remission ranged from 30 days to 230 days. 4) The toxicity of the regimen was tolerated. Moderate or severe toxicity evaluated on a per cycle basis included : neutropenia 52.5%, thrombocytopenia 45%, hemorrhagic cystitis 12.5% and mucositis 2.5%. 5) Two patients went on to bone marrow transplantation with histocompatibility matched sibling donors while in remission. CONCLUSION: The combination of ifosfamide and etoposide with mesna uroprotection has significant activity in relapsed refractory childhood lymphoblastic leukemia with tolerable toxicity. We recommended bone marrow transplantation after successful reinduction because of short remission duration of this regimen.
